Highly active antiretroviral therapy corrects hematopoiesis in HIV-1 infected patients: Interest for peripheral blood stem cell-based gene therapy

AIDS

Volumn 17, Issue 4, 2003, Pages 563-574

  Baillou, Claude ^a   Simon, Anne ^a   Leclercq, Virginie ^a   Azar, Nabih ^a   Rosenzwajg, Michele ^a   Herson, Serge ^a   Klatzmann, David ^a   Lemoine, François M ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

Author keywords

CD34; G CSF; HAART; Hematopoiesis; HIV 1; Retroviral gene therapy

Indexed keywords

ANALGESIC AGENT; ANTIRETROVIRUS AGENT; CD34 ANTIGEN; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RETROVIRUS VECTOR; RITONAVIR; STAVUDINE; ZIDOVUDINE;

ADULT; ARTICLE; BONE PAIN; CELL ACTIVATION; CELL CULTURE; CELL CYCLE; CLINICAL ARTICLE; CLONOGENESIS; CONTROLLED STUDY; GENE THERAPY; HEMATOPOIESIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOPHENOTYPING; LEUKAPHERESIS; MALE; MYALGIA; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; SEROLOGY; SIDE EFFECT; SIGNAL TRANSDUCTION; STEM CELL; SYMPTOMATOLOGY; VIRUS LOAD; VIRUS REPLICATION;

ANTIGENS, CD34; ANTIGENS, THY-1; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; GENE THERAPY; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETROVIRIDAE; TRANSDUCTION, GENETIC; VIRAL LOAD; VIRUS INTEGRATION;

EID: 0037423894     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200303070-00012     Document Type: Article

References (48)

1. Palella FJJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998, 338:853-860.
2. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999, 131:81-87.
3. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet 2000, 356:1423-1430.
4. Ledergerber B, Egger M, Opravil M, Telenti A, Hirschel B, Battegay M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Swiss HIV Cohort Study. Lancet 2000, 353:863-868.
5. Poeschla E, Corbeau P, Wong-Staal F. Development of HIV vectors for anti-HIV gene therapy. Proc Natl Acad Sci USA 1996, 93:11395-11399.
6. Statham S, Morgan RA. Gene therapy clinical trials for HIV. Curr Opin Mol Ther 1999 4:430-436.
7. Buchschacher GLJ, Wong-Staal F. Approaches to gene therapy for human immunodeficiency virus infection. Hum Gene Ther 2001, 12:1013-1019.
8. Hanenberg H, Hashino K, Konishi H, Hock RA, Kato I, Williams DA. Optimization of fibronectin-assisted retroviral gene transfer into human CD34+ hematopoietic cells. Hum Gene Ther 1997, 8:2193-2206.
9. Movassagh M, Desmyter C, Baillou C, Chapel-Fernandes S, Guigon M, Klatzmann D, et al. High level gene transfer to cord blood progenitors using gibbon ape leukemia virus pseudotype retroviral vectors and an improved clinically applicable protocol. Hum Gene Ther 1998, 9:225-234.
10. Movassagh M, Baillou C, Cosset FL, Klatzmann D, Guigon M, Lemoine FM. High level of retrovirus-mediated gene transfer into dendritic cells derived from cord blood and mobilized peripheral blood CD34+ cells. Hum Gene Ther 1999, 10:175-187.
11. Woods NB, Fahlman C, Mikkola H, Hamaguchi I, Olsson K, Zufferey R, et al. 2000. Lentiviral gene transfer into primary and secondary NOD/SCID repopulating cells. Blood 2000, 96:3725-3733.
12. Sirven A, Ravet E, Charneau P, Zennou V, Coulombel L, Guetard D, et al. Enhanced transgene expression in cord blood CD34(+)-derived hematopoietic cells, including developing T cells and NOD/SCID mouse repopulating cells, following transduction with modified trip lentiviral vectors. Mol Ther 2001, 3:438-448.
13. Scherr M, Battmer K, Blomer U, Schiedlmeier B, Ganser A, Grez M, et al. Lentiviral gene transfer into peripheral blood-derived CD34+ NOD/SCID-repopulating cells. Blood 2002, 99:709-712.
14. Cavazzana-Calvo M, Hacein-Bey S, de Saint Basile G, Gross F, Yvon E, Nusbaum P, et al. Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. Science 2000, 288:669-672.
15. Donahue RE, Johnson MM, Zon LI, Clark SC, Groopman JE. Suppression of in vitro haematopoiesis following human immunodeficiency virus infection. Nature 1987, 326:200-203.
16. Moses A, Nelson J, Bagby GC, Jr. The influence of human immunodeficiency virus-1 on hematopoiesis. Blood 1998, 91:1479-1495.
17. Jenkins M, Hanley MB, Moreno MB, Wieder E, McCune JM. Human immunodeficiency virus-1 infection interrupts thymopoiesis and multilineage hematopoiesis in vivo. Blood 1998, 91:2672-2678.
18. Adams GB, Pym AS, Poznansky MC, McClure MO, and Weber JN. The in vivo effects of combination antiretroviral drug therapy on peripheral blood CD34+ cell colony-forming units from HIV type-1 infected patients. AIDS Res Hum Retroviruses 1999, 15:551-559.
19. Charbord P, Newton I, Voillat L, Schaal JP, Herve P. The purification of CD34 cells from human cord blood: comparison of separation techniques and cytokine requirements for optimal growth of clonogenic progenitors. Br J Haematol 1996, 94:449-454.
20. Movassagh M, Caillot L, Baillou C, Guigon M, Lemoine FM. Optimization of the cycling of clonogenic and primitive cord blood progenitors by growth factors. Stem Cells 1997, 15:214-222.
21. Pontvert-Delucq S, Breton-Gorius J, Schmitt C, Baillou C, Guichard J, Najman A, et al. Characterization and functional analysis of adult human bone marrow cell subsets in relation to B-lymphoid development. Blood 1993, 82:417-429.
22. Issaad C, Croisille L, Katz A, Vainchenker W, Coulombel L. A murine stromal cell line allows the proliferation of very primitive human CD34++/CD38- progenitor cells in long-term cultures and semi-solid assays. Blood 1993, 81:2916-2924.
23. Sutherland HJ, Lansdorp PM, Henkelman DH, Eaves AC, Eaves CJ. Functional characterization of individual human hematopoietic stem cells cultured at limiting dilution on supportive marrow stromal layers. Proc Natl Acad Sci USA 1990, 87:3584-3588.
24. Giarratana MC, Kobari L, Neildez Nguyen TM, Firat H, Bouchet S, Lopez M, et al. Cell culture bags allow a large extent of ex vivo expansion of LTC-1C and functional mature cells which can subsequently be frozen: interest for a large-scale clinical applications. Bone Marrow Transplant 1998, 22:707-715.
25. Bonnet D, Lemoine F M, Pontvert-Delucq S, Baillou C, Najman A, Guigon M. Direct and reversible inhibitory effect of the tetrapeptide acetyl-N-Ser-Asp-Lys-Pro (Seraspenide) on the growth of human CD34+ subpopulations in response to growth factors. Blood 1993, 82:3307-3314.
26. Laure F, Courgnaud V, Rouzioux C, Blanche S, Veber F, Burgard M, et al. Detection of HIV1 DNA in infants and children by means of the polymerase chain reaction. Lancet 1988, 2:538-541.
27. Canque B, Rosenzwajg M, Camus S, Yagello M, Bonnet ML, Guigon M, et al. The effect of in vitro human immunodeficiency virus infection on dendritic-cell differentiation and function. Blood 1996, 88:4215-4228.
28. Gurman G, Dilek I, Arslan O, Arat M, Beksac M, Ilhan O, et al. The effect of G-CSF on lymphocyte subsets and CD34+ cells in allogeneic stem cell transplantation. Science 2001, 1:23-28.
29. Tayebi H, Kuttler F, Saas P, Lienard A, Petracca B, Lapierre V, et al. Effect of granulocyte colony-stimulating factor mobilization on phenotypical and functional properties of immune cells. Exp Hematol 2001, 4:458-470.
30. Galy A, Travis M, Cen D, Chen B. Human T, B, natural killer, and dendritic cells arise from a common bone marrow progenitor cell subset. Immunity 1995, 3:459-473.
31. Long H, Gaffney P, Mortari F, Miller JS. CD3 gamma, CD3 delta, and CD3 zeta mRNA in adult human marrow hematopoietic progenitors correlates with surface CD2 and CD7 expression. Exp Hematol 1996, 24:1402-1408.
32. Roe T, Reynolds TC, Yu G, Brown PO. Integration of murine leukemia virus DNA depends on mitosis. EMBO J 1993, 12:2099-2108.
33. Slobod KS, Bennett TA, Freiden PJ, Kechli AM, Howlett N, Flynn PM, et al. Mobilization of CD34+ progenitor cells by granulocyte colony-stimulating factor in human immunodeficiency virus type 1-infected adults. Blood 1996, 88:3329-3335.
34. Gervaix A, Schwarz L, Law P, Ho AD, Looney D, Lane T, et al. Gene therapy targeting peripheral blood CD34+ hematopoietic stem cells of HIV-infected individuals. Hum Gene Ther 1997, 8:2229-2238.
35. Junker U, Moon JJ, Kalfoglou CS, Sniecinski I, Forman SJ, Zaia JA, et al. Hematopoietic potential and retroviral transduction of CD34+ Thy-1+ peripheral blood stem cells from asymptomatic human immunodeficiency virus type-1-infected individuals mobilized with granulocyte colony-stimulating factor. Blood 1997, 89:4299-4306.
36. Law P, Lane TA, Gervaix A, Looney D, Schwarz L, Young D, et al. Mobilization of peripheral blood progenitor cells for human immunodeficiency virus-infectedindividuals. Exp Hematol 1999, 147-154.
37. Campbell TB, Sevin A, Coombs RW, Peterson GC, Rosandich M, Kuritzkes DR, et al. Changes in human immunodeficiency virus type 1 virus load during mobilization and harvesting of hemopoietic progenitor cells. Adult AIDS Clinical Trials Group 285 Study Team. Blood 2000, 95:48-55.
38. Levesque JP, Takamatsu Y, Nilsson SK, Haylock DN, Simmons PJ. Vascular cell adhesion molecule-1 (CD106) is cleaved by neutrophil proteases in the bone marrow following hematopoietic progenitor cell mobilization by granulocyte colony-stimulating factor. Blood 2001, 98:1289-1297.
39. Bender JG, To LB, Williams S, Schwartzberg LS. Defining a therapeutic dose of peripheral blood stem cells. J Hematother 1992, 1:329-341.
40. Schooley RT, Mladenovic J, Sevin A, ChiuS, Miles SA, Pomerantz RJ, et al. Reduced mobilization of CD34+ stem cells in advanced human immunodeficiency virus type 1 disease. J Infect Dis 2000, 181:148-157.
41. Marandin A, Katz A, Oksenhendler E, Tulliez M, Picard F, Vainchenker W, et al. Loss of primitive hematopoietic progenitors in patients with human immunodeficiency virus infection. Blood 1996, 88:4568-4578.
42. Isgro A, Mezzaroma I, Aiuti A, De Vita L, Franchi F, Pandolfi F, et al. Recovery of hematopoietic activity in bone marrow from human immunodeficiency virus type 1-infected patients during highly active antiretroviral therapy. AIDS Res Hum Retroviruses 2000, 16:1471-1479.
43. Dam Nielsen S, Kjaer Ersboll A, Mathiesen L, Nielsen JO, Hansen JE. Highly active antiretroviral therapy normalizes the function of progenitor cells in human immunodeficiency virus-infected patients. J Infect Dis 1998, 178:1299-1305.
44. Sloand EM, Maciejewski J, Kumar P, Kim S, Chaudhuri A, Young N. Protease inhibitors stimulate hematopoiesis and decrease apoptosis and ICE expression in CD34(+) cells. Blood 2000, 96:2735-2739.
45. Thiebot H, Louache F, Vaslin B, de Revel T, Neildez O, Larghero J, et al. Early and persistent bone marrow hematopoiesis defect in simian/human immunodeficiency virus-infected macaques despite efficient reduction of viremia by highly active antiretroviral therapy during primary infection. J Virol 2001, 75:11594-11602.
46. Lambotte O, Taoufik Y, de Goer MG, Wallon C, Goujard C, Delfraissy JF. Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2000, 23:114-119.
47. Sonza S, Mutimer HP, Oelrichs R, Jardine D, Harvey K, Dunne A, et al. Monocytes harbour replication-competent, non-latent HIV-1 in patients on highly active antiretroviral therapy. AIDS 2001, 15:17-22.
48. Bauer G, Valdez P, Kearns K, Bahner I, Wen SF, Zaia JA, et al. Inhibition of human immunodeficiency virus-1 (HIV-1) replication, after transduction of granulocyte colony-stimulating factor-mobilized CD34+ cells from HIV-1-infected donors using retroviral vectors containing anti-HIV-1 genes. Blood 1997, 89:2259-2267.